News

AOC 001 previously demonstrated benefit in patients in the phase 2 MARINA trial.

The cofounder and chief scientific officer at Earli discussed the company’s unique approach to cancer diagnosis.

The FDA granted the designation after reviewing safety and efficacy data from phase 1 of the trial.

Ineka Whiteman, PhD, head of research and medical affairs, BDSRA Australia, discussed what has occurred in the field of Batten disease gene therapy in the past year.

The director of the Mount Sinai Fuster Heart Hospital discussed how artificial intelligence complements data-driven research.

The McCaw Endowed Chair of Muscular Dystrophy at University of Washington discussed the role the ASGCT plays in the field.

The phase 1/2 trial is proceeding to its phase 2 trial after safety was demonstrated in its first phase.

The chief of cardiology at Weill Cornell Medical College discussed the center’s increased focus on genetic research.

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.

Candel also recently received orphan drug designation for CAN-3110 for treating recurrent, high-grade glioma.

The Don and Marilyn Anderson Professor of Oncology at University of Wisconsin – Madison shared highlights from the discussion.

Catch up on any of the key data updates you may have missed last month, with coverage highlights from the CGTLive™ team.

The chief product officer at Mission Bio discussed the company’s Genome Editing Solution.

Review top news and interview highlights from the week ending June 7, 2024.

Nine of 14 participants receiving EDIT-101 had meaningful improvements in at least 1 key functional outcome.

ADI-001 is also being evaluated in a phase 1 study in patients with B-cell non-Hodgkin lymphoma.

The professor in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center discussed the advantages the newly approved CAR-T has for older, frailer patients.

BSB-1001 targets HA-1 miHA and will be evaluated in the 1 phase 1/2a TCX-101 trial.

The associate professor of clinical pediatrics at Cincinnati Children's discussed further investigations into novel therapies and new research.

Other of the company’s RNAi therapies have recently shown promising data in hyperlipidemia and asthma.

According to recent studies and the latest insights provided by experts, early developments in gene and cell therapies show promise for patients living with Parkinson disease, but challenges remain.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The professor of pediatric hematology/oncology at CS Mott Children’s Hospital discussed a sub analysis of the HOPE-B trial.

Nine responses were ongoing as of the March 2023 cutoff date.

The assistant professor at Moffit Cancer Center discussed the subgroup analysis she presented at ASCO’s 2024 Annual Meeting.

GCC19CART targets both guanylate cyclase 2C and CD19.

The Chief Medical Officer of Addimmune discussed the unmet need with HIV and research the company is conducting.

Of 300 screened participants, 68 have been matched by target antigen and HLA expression to a TCR-T in the ImmunoBank.